Quarterly ResultMay 5, 2026, 06:53 AM
Pediatrix Q1 Adjusted EPS $0.44; Net Revenue $476M
AI Summary
Pediatrix Medical Group reported strong first-quarter results for 2026, with Adjusted EPS of $0.44 and net revenue of $476.2 million, exceeding expectations due to top-line growth. Net income increased to $29.6 million from $20.7 million in the prior-year period. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, highlighting a healthy balance sheet and robust cash flow for future opportunities.
Key Highlights
- Adjusted EPS for Q1 2026 was $0.44, up from $0.33 in Q1 2025.
- Net revenue for Q1 2026 reached $476.2 million, compared to $458.4 million in Q1 2025.
- Net income for Q1 2026 was $29.6 million, an increase from $20.7 million in Q1 2025.
- Adjusted EBITDA for Q1 2026 grew to $58.2 million from $49.2 million in Q1 2025.
- Same-unit revenue increased by 2.8%, driven by a 4.4% rise in reimbursement-related factors.
- Cash and cash equivalents stood at $205.8 million as of March 31, 2026.
- Total debt outstanding was $591 million at March 31, 2026.
- Reaffirmed full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million.